Press Releases

Date Title and Summary Additional Formats
Toggle Summary Evoke Pharma Announces the Completion of Enrollment in Its Thorough ECG Study for EVK-001
SOLANA BEACH, Calif. , Sept. 9, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has completed enrollment in its thorough ECG (QT) study of EVK-001, the Company's lead
View HTML
Toggle Summary Evoke Pharma to Present at the Aegis Capital Corp. 2014 Healthcare & Technology Conference
SOLANA BEACH, Calif. , Sept. 4, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer , CEO, will present a corporate overview at the Aegis Capital Corp.
View HTML
Toggle Summary Evoke Pharma Reports Second Quarter 2014 Results
SOLANA BEACH, Calif. , Aug. 13, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the second quarter ended June 30, 2014 .
View HTML
Toggle Summary Evoke Pharma Announces Initiation of a Thorough ECG (QT) Study for EVK-001
SOLANA BEACH, Calif. , Aug. 12, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the initiation of its thorough ECG (QT) study of the Company's lead product candidate, EVK-001,
View HTML
Toggle Summary Evoke Pharma Schedules Webcast and Conference Call for Second Quarter 2014 Financial Results
SOLANA BEACH, Calif. , July 30, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the second quarter of 2014 on Wednesday, August 13,
View HTML
Toggle Summary Evoke Pharma Secures $4.5 Million Loan Facility With Square 1 Bank
SOLANA BEACH, Calif. , May 28, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has secured a $4.5 million term loan agreement with Square 1 Bank (Nasdaq:SQBK).
View HTML
Toggle Summary Evoke Pharma Reports First Quarter 2014 Results
SOLANA BEACH, Calif. , May 13, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the first quarter ended March 31, 2014 .
View HTML
Toggle Summary Evoke Pharma Schedules Webcast and Conference Call for First Quarter 2014 Financial Results
SOLANA BEACH, Calif. , May 6, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the First Quarter of 2014 on Tuesday, May 13, 2014 ,
View HTML
Toggle Summary Evoke Pharma Announces That EVK-001 Phase 2b Results Will be Presented at Digestive Disease Week 2014
SOLANA BEACH, Calif. , April 28, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that data from the Company's Phase 2b clinical trial of EVK-001, a novel intranasal formulation
View HTML
Toggle Summary Evoke Pharma Initiates Phase 3 Clinical Trial of EVK-001 for Treatment of Gastroparesis
First Patient Enrolled in Study of Novel Intranasal Formulation and Delivery of Metoclopramide
View HTML